Genomic Health, Inc. (GHDX) COO Frederic Pla Sells 43,500 Shares

Genomic Health, Inc. (NASDAQ:GHDX) COO Frederic Pla sold 43,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $84.91, for a total transaction of $3,693,585.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Frederic Pla also recently made the following trade(s):

  • On Monday, October 8th, Frederic Pla sold 1,500 shares of Genomic Health stock. The stock was sold at an average price of $65.43, for a total transaction of $98,145.00.

Shares of NASDAQ GHDX traded down $2.11 during trading on Friday, reaching $81.67. 1,054,132 shares of the stock were exchanged, compared to its average volume of 332,033. Genomic Health, Inc. has a twelve month low of $26.54 and a twelve month high of $92.18. The stock has a market cap of $3.23 billion, a P/E ratio of 8,167.00 and a beta of 0.44.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Tuesday, November 6th. The medical research company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.28. Genomic Health had a net margin of 4.95% and a return on equity of 14.76%. The business had revenue of $101.30 million for the quarter, compared to analysts’ expectations of $94.27 million. During the same period in the previous year, the company posted ($0.06) earnings per share. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, equities analysts forecast that Genomic Health, Inc. will post 1.06 earnings per share for the current fiscal year.

GHDX has been the subject of several research reports. TheStreet upgraded shares of Genomic Health from a “c” rating to a “b-” rating in a research note on Friday, August 3rd. Canaccord Genuity boosted their price objective on shares of Genomic Health from $56.00 to $62.00 and gave the stock a “buy” rating in a research note on Friday, August 3rd. Zacks Investment Research upgraded shares of Genomic Health from a “hold” rating to a “buy” rating and set a $61.00 price objective for the company in a research note on Monday, August 6th. BidaskClub downgraded shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 4th. Finally, Cowen reiterated a “hold” rating and set a $50.00 price objective on shares of Genomic Health in a research note on Monday, August 6th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, two have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $48.33.

Several hedge funds and other institutional investors have recently bought and sold shares of GHDX. Russell Investments Group Ltd. lifted its position in shares of Genomic Health by 894.1% during the first quarter. Russell Investments Group Ltd. now owns 42,449 shares of the medical research company’s stock worth $1,328,000 after purchasing an additional 38,179 shares in the last quarter. Guggenheim Capital LLC acquired a new stake in Genomic Health in the first quarter valued at $264,000. Legal & General Group Plc raised its holdings in Genomic Health by 67.8% in the first quarter. Legal & General Group Plc now owns 12,300 shares of the medical research company’s stock valued at $385,000 after acquiring an additional 4,968 shares in the last quarter. Allianz Asset Management GmbH raised its holdings in Genomic Health by 2.4% in the first quarter. Allianz Asset Management GmbH now owns 77,515 shares of the medical research company’s stock valued at $2,425,000 after acquiring an additional 1,840 shares in the last quarter. Finally, Hartford Investment Management Co. acquired a new stake in Genomic Health in the second quarter valued at $320,000. 89.90% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Genomic Health, Inc. (GHDX) COO Frederic Pla Sells 43,500 Shares” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://sportsperspectives.com/2018/11/10/genomic-health-inc-ghdx-coo-frederic-pla-sells-43500-shares.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Read More: Insider Trading

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply